BioNTech SE (NASDAQ: BNTX) had its price target lowered by analysts at Morgan Stanley from $145.00 to $139.00. They now have an "overweight" rating on the stock.
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]Yahoo! Finance
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.MarketBeat
- BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast CancerGlobeNewswire
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 12/9/25 - Form 6-K
- 12/8/25 - Form 6-K
- 12/3/25 - Form 6-K
- BNTX's page on the SEC website